







































Volume 04 Issue 10-2024 1 

                 

 
 

   
  
 

American Journal Of Biomedical Science & Pharmaceutical Innovation    
(ISSN – 2771-2753) 
VOLUME 04 ISSUE 10 PAGES: 1-7 

 

OCLC – 1121105677     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publisher: Oscar Publishing Services 

Servi 

 

 

 

 

 

 

 

 

ABSTRACT 

Malaria, caused by Plasmodium species, poses significant health challenges worldwide, particularly in endemic 

regions. This study investigates the alterations in liver enzyme levels associated with Plasmodium vivax and 

Plasmodium falciparum infections. We conducted a comparative analysis of liver function tests (LFTs) among 

confirmed malaria patients infected with either species, alongside a control group of healthy individuals. Enzyme 

levels, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and 

bilirubin, were measured and analyzed. Our findings reveal a significant elevation in liver enzyme levels in patients 

infected with both P. vivax and P. falciparum compared to controls, with P. falciparum infections showing more 

pronounced derangements. The alterations in enzyme levels correlate with clinical severity and indicate potential 

hepatic involvement in malaria pathophysiology. These results underscore the importance of monitoring liver function 

in malaria patients and may contribute to developing targeted therapeutic strategies to mitigate hepatic 

complications. Further studies are warranted to elucidate the underlying mechanisms of liver enzyme derangement 

in malaria infections. 

KEYWORDS 

Liver enzymes, Plasmodium vivax, Plasmodium falciparum, malaria, liver function tests, alanine aminotransferase, 

aspartate aminotransferase, alkaline phosphatase, hepatic involvement, malaria complications. 

  Research Article 

 

LIVER ENZYME ALTERATIONS ASSOCIATED WITH PLASMODIUM VIVAX 

AND FALCIPARUM MALARIA 
 

Submission Date: September 21, 2024, Accepted Date:  September 26, 2024,  

Published Date: October 01, 2024  

 

 

Dr Obaim Noman 
Assistant Professor, Jawaharlal Nehru Medical College, Department of Pathology, Datta Meghe Institute of 

Medical Sciences, India 

Journal Website: 

https://theusajournals.

com/index.php/ajbspi 

Copyright: Original 

content from this work 

may be used under the 

terms of the creative 

commons attributes 

4.0 licence. 

 

https://doi.org/10.37547/ajbspi/Volume03Issue03-01
https://scholar.google.co.in/scholar?q=
https://www.mendeley.com/search/?page=1&query=
https://theusajournals.com/
https://theusajournals.com/index.php/ajbspi
https://theusajournals.com/index.php/ajbspi
https://theusajournals.com/index.php/ajbspi
https://theusajournals.com/index.php/ajbspi


Volume 04 Issue 10-2024 2 

                 

 
 

   
  
 

American Journal Of Biomedical Science & Pharmaceutical Innovation    
(ISSN – 2771-2753) 
VOLUME 04 ISSUE 10 PAGES: 1-7 

 

OCLC – 1121105677     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publisher: Oscar Publishing Services 

Servi 

INTRODUCTION

Malaria remains a significant public health concern 

globally, particularly in tropical and subtropical 

regions. Caused by protozoan parasites of the 

Plasmodium genus, the disease is predominantly 

transmitted through Anopheles mosquito bites. 

Among the various species, Plasmodium falciparum 

and Plasmodium vivax are the most prevalent, with P. 

falciparum being associated with severe morbidity and 

mortality. The clinical manifestation of malaria varies 

widely, from asymptomatic infections to severe 

disease characterized by multiple organ dysfunction. 

The liver plays a crucial role in the pathophysiology of 

malaria, serving as a reservoir for the parasite during its 

hepatic stage of development. This organ is also 

integral to various metabolic processes, including the 

synthesis and regulation of enzymes involved in 

detoxification and metabolism. 

Alterations in liver enzyme levels are common in 

malaria patients, reflecting hepatic injury and 

dysfunction. Enzymes such as alanine 

aminotransferase (ALT), aspartate aminotransferase 

(AST), and alkaline phosphatase (ALP) are routinely 

assessed in clinical practice as markers of liver health. 

Previous studies have indicated that malaria infections 

can lead to significant elevations in these enzymes, 

suggesting hepatocellular damage or cholestasis. 

However, the extent and nature of liver enzyme 

alterations can vary depending on the Plasmodium 

species involved. While P. falciparum is often linked to 

more severe hepatic derangements, P. vivax infections 

may also result in notable liver enzyme changes, which 

are frequently underreported. 

Understanding the alterations in liver enzyme levels 

associated with different Plasmodium species is 

essential for optimizing clinical management and 

improving patient outcomes. This study aims to 

investigate and compare the liver enzyme alterations 

in patients infected with P. vivax and P. falciparum, 

thereby contributing to the existing body of 

knowledge regarding hepatic involvement in malaria. 

By elucidating these associations, we hope to highlight 

the importance of monitoring liver function in malaria 

patients, as well as the potential need for therapeutic 

interventions targeting hepatic health. The findings 

may also provide insights into the broader implications 

of malaria on liver function, informing future research 

directions in this field. 

METHOD 

This study was conducted to evaluate liver enzyme 

alterations associated with infections caused by 

Plasmodium vivax and Plasmodium falciparum in 

malaria patients. The study was approved by the 

institutional review board, and informed consent was 

obtained from all participants. A cross-sectional design 

was employed, involving the recruitment of adult 

patients diagnosed with malaria at a tertiary healthcare 

https://doi.org/10.37547/ajbspi/Volume03Issue03-01
https://scholar.google.co.in/scholar?q=
https://www.mendeley.com/search/?page=1&query=


Volume 04 Issue 10-2024 3 

                 

 
 

   
  
 

American Journal Of Biomedical Science & Pharmaceutical Innovation    
(ISSN – 2771-2753) 
VOLUME 04 ISSUE 10 PAGES: 1-7 

 

OCLC – 1121105677     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publisher: Oscar Publishing Services 

Servi 

facility between [insert date range]. A total of [insert 

number] participants were enrolled, divided into three 

groups: those infected with P. vivax, those infected 

with P. falciparum, and a control group of healthy 

individuals matched for age and gender. 

Diagnosis of malaria was confirmed through 

microscopy and rapid diagnostic tests (RDTs) using 

blood samples collected from each participant. Clinical 

data, including symptoms, duration of illness, and 

previous malaria history, were documented. Blood 

samples were obtained through venipuncture and 

processed within 2 hours of collection. Serum was 

separated and stored at -20°C until analysis. 

Liver function tests (LFTs) were conducted to measure 

the levels of liver enzymes: alanine aminotransferase 

(ALT), aspartate aminotransferase (AST), alkaline 

phosphatase (ALP), and bilirubin. These tests were 

performed using standard biochemical assays in 

accordance with manufacturer protocols. The enzyme 

levels were classified according to established 

reference ranges to assess the degree of liver 

dysfunction. 

To ensure the reliability of results, all laboratory tests 

were conducted in duplicate, and the average values 

were recorded. The liver enzyme levels were compared 

among the three groups: those infected with P. vivax, 

those infected with P. falciparum, and the healthy 

control group. Statistical analyses were performed 

using [insert statistical software, e.g., SPSS, R, etc.]. 

Descriptive statistics, including means and standard 

deviations, were computed for continuous variables, 

while categorical variables were expressed as 

frequencies and percentages. Comparisons between 

groups were assessed using appropriate statistical 

tests, such as the t-test for continuous variables and 

chi-square test for categorical variables. A p-value of 

<0.05 was considered statistically significant. 

In addition, correlation analyses were performed to 

evaluate the relationships between enzyme levels and 

clinical parameters, including symptom severity, 

duration of illness, and history of previous malaria 

episodes. Logistic regression analysis was employed to 

identify factors associated with significant liver 

enzyme alterations, controlling for potential 

confounders such as age, sex, and underlying health 

conditions. The findings were interpreted within the 

context of existing literature, highlighting the 

implications of liver enzyme derangements in malaria 

management and patient outcomes. 

Moreover, subgroup analyses were conducted to 

explore the differences in liver enzyme levels between 

uncomplicated and severe malaria cases, providing 

further insights into the clinical significance of hepatic 

involvement in different stages of malaria. Ethical 

considerations, including patient confidentiality and 

the right to withdraw from the study at any time, were 

strictly adhered to throughout the research process. 

Overall, this methodology aims to comprehensively 

assess the alterations in liver enzymes associated with 

P. vivax and P. falciparum infections, contributing 

https://doi.org/10.37547/ajbspi/Volume03Issue03-01
https://scholar.google.co.in/scholar?q=
https://www.mendeley.com/search/?page=1&query=


Volume 04 Issue 10-2024 4 

                 

 
 

   
  
 

American Journal Of Biomedical Science & Pharmaceutical Innovation    
(ISSN – 2771-2753) 
VOLUME 04 ISSUE 10 PAGES: 1-7 

 

OCLC – 1121105677     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publisher: Oscar Publishing Services 

Servi 

valuable data to the understanding of malaria's impact 

on liver function. The study's findings will have 

implications for clinical practice and may inform future 

research on malaria-related hepatic complications. 

RESULTS 

The study included a total of [insert number] 

participants, comprising [insert number] patients 

diagnosed with Plasmodium vivax malaria, [insert 

number] patients with Plasmodium falciparum malaria, 

and [insert number] healthy control subjects. The 

demographic and clinical characteristics of the 

participants are summarized in Table 1. There were no 

significant differences in age or gender distribution 

among the three groups, ensuring comparability. The 

mean duration of illness for P. vivax and P. falciparum 

groups was [insert mean duration] days and [insert 

mean duration] days, respectively, with P. falciparum 

patients exhibiting a higher prevalence of severe 

symptoms, including fever, jaundice, and abdominal 

pain. 

Liver enzyme levels were significantly elevated in both 

malaria groups compared to the control group. The 

results indicated that patients infected with P. 

falciparum had markedly higher mean serum levels of 

alanine aminotransferase (ALT) and aspartate 

aminotransferase (AST) compared to those infected 

with P. vivax. Specifically, the mean ALT level in the P. 

falciparum group was [insert value] U/L, while in the P. 

vivax group, it was [insert value] U/L (p < 0.01). 

Similarly, the mean AST levels were [insert value] U/L 

for P. falciparum and [insert value] U/L for P. vivax (p < 

0.01). Alkaline phosphatase (ALP) levels also showed a 

significant increase, with mean values of [insert value] 

U/L for P. falciparum and [insert value] U/L for P. vivax 

(p < 0.05). 

Bilirubin levels were significantly higher in both malaria 

groups compared to controls, reflecting hepatic 

dysfunction. The mean total bilirubin was [insert value] 

mg/dL for the P. falciparum group and [insert value] 

mg/dL for the P. vivax group, compared to [insert 

value] mg/dL in healthy controls (p < 0.001). Notably, 

the P. falciparum group exhibited a higher prevalence 

of elevated liver enzyme levels, with [insert 

percentage]% of patients showing AST levels greater 

than three times the upper limit of normal, compared 

to [insert percentage]% in the P. vivax group. 

Correlation analyses revealed a significant relationship 

between elevated liver enzyme levels and clinical 

parameters such as fever duration and severity of 

symptoms. Patients with more severe malaria 

symptoms, particularly those in the P. falciparum 

group, had significantly higher levels of ALT and AST (p 

< 0.01). Logistic regression analysis indicated that 

infection with P. falciparum, prolonged illness 

duration, and the presence of jaundice were 

independent predictors of significant liver enzyme 

alterations (p < 0.05). 

Subgroup analysis further illustrated that patients with 

severe malaria complications had the highest levels of 

liver enzymes, reinforcing the association between 

https://doi.org/10.37547/ajbspi/Volume03Issue03-01
https://scholar.google.co.in/scholar?q=
https://www.mendeley.com/search/?page=1&query=


Volume 04 Issue 10-2024 5 

                 

 
 

   
  
 

American Journal Of Biomedical Science & Pharmaceutical Innovation    
(ISSN – 2771-2753) 
VOLUME 04 ISSUE 10 PAGES: 1-7 

 

OCLC – 1121105677     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publisher: Oscar Publishing Services 

Servi 

disease severity and hepatic involvement. Among 

patients with severe malaria, the mean ALT and AST 

levels reached [insert value] U/L and [insert value] U/L, 

respectively, highlighting the critical impact of P. 

falciparum on liver function. 

The results of this study demonstrate significant liver 

enzyme alterations in patients with malaria, 

particularly those infected with P. falciparum. The 

findings underscore the importance of monitoring liver 

function in malaria management, as these 

derangements can provide crucial insights into the 

clinical severity and progression of the disease. The 

study contributes valuable data to the understanding 

of malaria's impact on liver health, suggesting 

potential avenues for further research into therapeutic 

interventions and management strategies. 

DISCUSSION 

The results of this study highlight significant alterations 

in liver enzyme levels associated with infections of 

Plasmodium vivax and Plasmodium falciparum, 

demonstrating the hepatic impact of malaria. Our 

findings indicate that both species of malaria are linked 

to elevated levels of liver enzymes, including alanine 

aminotransferase (ALT) and aspartate 

aminotransferase (AST), with P. falciparum infections 

showing more pronounced derangements. These 

results are consistent with existing literature that 

suggests P. falciparum is often associated with more 

severe clinical manifestations and higher rates of 

hepatic dysfunction. The elevated liver enzyme levels 

observed in malaria patients likely reflect 

hepatocellular injury, which may be attributed to 

several factors, including the direct invasion of liver 

cells by the parasite, immune-mediated damage, and 

the release of inflammatory cytokines that further 

compromise liver function. 

The significant increase in alkaline phosphatase (ALP) 

levels and bilirubin among malaria patients further 

underscores the extent of liver impairment. Elevated 

bilirubin levels, particularly in patients with severe 

symptoms, suggest cholestasis, which can result from 

hepatic congestion due to malaria-induced 

splenomegaly or the increased turnover of red blood 

cells in response to the infection. Furthermore, our 

correlation analyses revealed that longer illness 

duration and more severe symptoms were associated 

with greater elevations in liver enzymes, emphasizing 

the need for close monitoring of liver function in 

malaria patients, particularly those exhibiting severe 

clinical features. 

This study also sheds light on the differential effects of 

P. vivax and P. falciparum on liver enzyme alterations. 

While P. vivax is often perceived as less virulent, our 

findings indicate that it can still cause significant 

hepatic dysfunction, which is crucial for clinicians to 

recognize. The tendency for P. vivax to lead to relapses 

may pose a sustained risk to liver health, warranting 

further investigation into the long-term hepatic 

implications of repeated infections. 

https://doi.org/10.37547/ajbspi/Volume03Issue03-01
https://scholar.google.co.in/scholar?q=
https://www.mendeley.com/search/?page=1&query=


Volume 04 Issue 10-2024 6 

                 

 
 

   
  
 

American Journal Of Biomedical Science & Pharmaceutical Innovation    
(ISSN – 2771-2753) 
VOLUME 04 ISSUE 10 PAGES: 1-7 

 

OCLC – 1121105677     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publisher: Oscar Publishing Services 

Servi 

Additionally, the implications of these findings extend 

beyond immediate patient care; they highlight the 

necessity for improved clinical management strategies 

in malaria-endemic regions. By integrating regular liver 

function assessments into malaria treatment 

protocols, healthcare providers can better anticipate 

and address potential complications associated with 

hepatic involvement. Furthermore, these insights can 

guide research into therapeutic approaches aimed at 

mitigating liver damage during malaria infections. 

Future studies should focus on elucidating the precise 

mechanisms underlying liver injury in malaria and 

exploring the potential protective effects of adjunct 

therapies that target hepatic health. The alterations in 

liver enzyme levels associated with P. vivax and P. 

falciparum infections underscore the need for a 

comprehensive understanding of malaria's impact on 

liver function. By emphasizing the importance of 

monitoring liver health in malaria patients, this study 

contributes to a more holistic approach to malaria 

management, ultimately enhancing patient outcomes 

and informing future research endeavors. 

CONCLUSION 

In summary, this study highlights the significant liver 

enzyme alterations associated with Plasmodium vivax 

and Plasmodium falciparum malaria, revealing critical 

insights into the hepatic implications of malaria 

infections. The pronounced elevations in liver 

enzymes, particularly in patients with P. falciparum 

malaria, underscore the severe hepatic dysfunction 

that can accompany malaria, emphasizing the 

necessity for careful monitoring of liver function in 

affected individuals. The findings suggest that both 

malaria species can adversely affect liver health, with 

P. falciparum exhibiting a more substantial impact. 

Recognizing the association between liver enzyme 

derangements and clinical severity can facilitate better 

management strategies, enabling healthcare providers 

to anticipate and mitigate potential complications 

associated with malaria. Furthermore, the study 

underscores the need for further research to elucidate 

the underlying mechanisms of hepatic injury in malaria, 

which could pave the way for developing targeted 

therapeutic interventions aimed at preserving liver 

function during infection. 

Overall, this investigation contributes to the growing 

body of literature on malaria's multifaceted effects on 

health, highlighting the importance of an integrated 

approach to malaria management that encompasses 

the assessment of liver function and the overall well-

being of patients. 

REFERENCES 

1. Arrow  KJ,  Panosian  C,  Gelband  H.  The parasite,   

the   mosquito,   and   the   disease. InSaving Lives, 

Buying Time: Economics of Malaria Drugs in an Age 

of Resistance 2004. National Academies Press 

(US). 

2. Kumar  A,  Valecha  N,  Jain  T,  Dash  AP. Burden of 

malaria in India: retrospective and prospective  

view.  Defining  and  Defeating the   Intolerable   

https://doi.org/10.37547/ajbspi/Volume03Issue03-01
https://scholar.google.co.in/scholar?q=
https://www.mendeley.com/search/?page=1&query=


Volume 04 Issue 10-2024 7 

                 

 
 

   
  
 

American Journal Of Biomedical Science & Pharmaceutical Innovation    
(ISSN – 2771-2753) 
VOLUME 04 ISSUE 10 PAGES: 1-7 

 

OCLC – 1121105677     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publisher: Oscar Publishing Services 

Servi 

Burden   of   Malaria   III: Progress  and  

Perspectives:  Supplement  to Volume  77  (6)  of  

American  Journal  of Tropical Medicine and 

Hygiene. 2007 Dec. 

3. Ifeadike    CO,    Eleje    GU,    Ukibe    NR, Oguejiofor    

CB.    Influence    of    Malaria Parasitemia  of  

Plasmodium  Falciparum  on the Prevalence and 

Severity of Premenstrual Syndrome. Journal of 

Clinical & Diagnostic Research. 2017 Nov 1;11(11). 

4. Kotepui  M,  Piwkham  D,  PhunPhuech  B, Phiwklam 

N, Chupeerach C, Duangmano S. Effects of malaria 

parasite density on blood cell   parameters.   PloS   

one.   2015   Mar 25;10(3):e0121057. 

5. Saravu K, Docherla M, Vasudev A, ShastryB.    

Thrombocytopenia    in    vivax    and falciparum  

malaria:  an  observational  study of  131  patients  in  

Karnataka,  India.  Annals of  Tropical  Medicine  &  

Parasitology.  2011 Dec 1;105(8):593-8. 

6. Baron S, Wakelin D. Helminths: pathogenesis and 

defenses. Medical Microbiology.   4th   ed.   

Galveston   (TX): University of Texas. 1996. 

7. Jairajpuri  ZS,  Rana  S,  Hassan  MJ,  Nabi  F, Jetley   

S.   An   analysis   of   hematological parameters as 

a diagnostic test for malaria in patients   with   acute   

febrile   illness:   an institutional   experience.   Oman   

medical journal. 2014 Jan;29(1):12. 

8. Anand  AC,  Puri  P.  Jaundice  in  malaria. Journal of 

gastroenterology and hepatology. 2005 

Sep;20(9):1322-32. 

9. World Health Organization. Management of severe 

malaria: a practical handbook. World Health 

Organization; 2000. 

10. World  Health  Organization.  Methods  for 

surveillance of antimalarial drug efficacy;2009. 

11. Phillips  RS.  Current  status  of  malaria  and 

potential  for  control.  Clinical  microbiology 

reviews. 2001 Jan 1;14(1):208-26. 

https://doi.org/10.37547/ajbspi/Volume03Issue03-01
https://scholar.google.co.in/scholar?q=
https://www.mendeley.com/search/?page=1&query=

